{"id":3798,"date":"2019-07-04T12:58:44","date_gmt":"2019-07-04T10:58:44","guid":{"rendered":"https:\/\/aa-pnh.pe-dev.de\/ravulizumab-ultomiris-approved-for-the-treatment-of-pnh\/"},"modified":"2021-12-27T10:01:12","modified_gmt":"2021-12-27T09:01:12","slug":"ravulizumab-ultomiris-approved-for-the-treatment-of-pnh","status":"publish","type":"post","link":"https:\/\/aa-pnh.org\/en\/ravulizumab-ultomiris-approved-for-the-treatment-of-pnh\/","title":{"rendered":"Ravulizumab (Ultomiris\u00ae) approved for the treatment of PNH!"},"content":{"rendered":"<p>On July 2nd, 2019, ravulizumab (Ultomiris&reg;) was approved in the EU for the treatment of adult patients with PNH. Patients are suitable for treatment<!--more--> with <a class=\"glossaryLink\" aria-describedby=\"tt\" data-cmtooltip=\"&lt;div class=glossaryItemTitle&gt;haemolysis&lt;\/div&gt;&lt;div class=glossaryItemBody&gt;Breakdown of red blood cells&lt;\/div&gt;\" href=\"https:\/\/aa-pnh.org\/en\/glossar\/haemolysis\/\" data-gt-translate-attributes='[{\"attribute\":\"data-cmtooltip\", \"format\":\"html\"}]' tabindex=\"0\" role=\"link\">haemolysis<\/a> and at least one other clinical symptom that indicates high disease activity, as well as clinically stable patients who have received eculizumab in the previous 6 months. <\/p>\n<p>Ravulizumab is a further development of the currently only available PNH drug eculizumab (Soliris&reg;) and only needs to be administered as an <a class=\"glossaryLink\" aria-describedby=\"tt\" data-cmtooltip=\"&lt;div class=glossaryItemTitle&gt;infusion&lt;\/div&gt;&lt;div class=glossaryItemBody&gt;Injection of a liquid into a vein&lt;\/div&gt;\" href=\"https:\/\/aa-pnh.org\/en\/glossar\/infusion\/\" data-gt-translate-attributes='[{\"attribute\":\"data-cmtooltip\", \"format\":\"html\"}]' tabindex=\"0\" role=\"link\">infusion<\/a> every 8 weeks instead of every 2 weeks as before. Studies have shown that ravulizumab is not inferior to its &ldquo;predecessor&rdquo; eculizumab in terms of efficacy and safety. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>On July 2nd, 2019, ravulizumab (Ultomiris&reg;) was approved in the EU for the treatment of adult patients with PNH. Patients are suitable for treatment<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"gallery","meta":{"footnotes":""},"categories":[81],"tags":[84],"class_list":["post-3798","post","type-post","status-publish","format-gallery","hentry","category-medication","tag-medication","post_format-post-format-gallery"],"_links":{"self":[{"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/posts\/3798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/comments?post=3798"}],"version-history":[{"count":0,"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/posts\/3798\/revisions"}],"wp:attachment":[{"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/media?parent=3798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/categories?post=3798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aa-pnh.org\/en\/wp-json\/wp\/v2\/tags?post=3798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}